A Cross-sectional Study to Investigate Prevalence of Systemic Inflammation (hsCRP) in Cohort of Patients With HF and a Cohort of Patients With ASCVD and CKD in the Middle East
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 756
- 试验地点
- 20
- 主要终点
- High Sensitivity C-Reactive Protein (hsCRP) ≥2 mg/L
研究概览
简要总结
This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease) with/without kidney disease.
The aim of the study is to assess the number of people with high levels of systemic inflammation among Middle East people with cardiovascular with/without kidney disease. Systemic inflammation means that it occurs throughout the body.
Participation in this study only requires a single visit at the clinic/hospital/medical institution. Participants will continue their normal care and will not get any treatment as part of this study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- •Male or female, age above or equal to 18 years at the time of signing informed consent.
- •Diagnosed with ASCVD+CKD and/or HF (pEF or mrEF)
排除标准
- •Previous participation in this study. Participation is defined as having given informed consent in this study.
- •Current participation (i.e., signed informed consent) in any other interventional clinical study.
- •Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization).
- •Clinical evidence, or suspicion of, active infection within the last 60 days.
- •Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
结局指标
主要结局
High Sensitivity C-Reactive Protein (hsCRP) ≥2 mg/L
时间窗: At Visit (day 0)
Count of patients
次要结局
未报告次要终点
